Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
about
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesRecent advances in treatment of heart failureEfficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysisBlood pressure and amiloride-sensitive sodium channels in vascular and renal cellsGetting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardiumEffects of spironolactone and losartan on the early neovascularization of acute myocardial infarction.Advances in treatment of hyperkalemia in chronic kidney disease.Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney diseaseSafety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.Cardiomyocyte and Vascular Smooth Muscle-Independent 11β-Hydroxysteroid Dehydrogenase 1 Amplifies Infarct Expansion, Hypertrophy, and the Development of Heart Failure After Myocardial Infarction in Male Mice.SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study.Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction.Loop diuretics and ultrafiltration in heart failure.Aldosterone receptor antagonists: current perspectives and therapiesMedication management of chronic heart failure in older adults.Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?Reverse remodelling and myocardial recovery in heart failure.Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications.Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease.Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic.Dilated Cardiomyopathy: Genetic Determinants and Mechanisms.Outpatient management of chronic heart failure.
P2860
Q26741152-D7C2CEFC-284F-4623-9B95-38F90C4D4E3EQ26766223-ADB8666B-3B8A-4479-807E-E9F895E27C31Q26773030-1ABF47C1-AA8B-4621-9DDF-A4514BD644EBQ27000436-531E4F14-692A-4FFB-BD2F-43918EEF3FD8Q28067162-EA2AA79C-628A-4A8E-95F8-70F6E3409A58Q33962156-1C5DA219-6136-452A-8849-07B7F6BBD173Q34491934-58E33CB7-6FAA-4BF2-9A58-C43FC85CE078Q35557972-7AE355DA-3A0E-43FB-939E-4F92F9ABA5ACQ35626544-0B9AB701-EC65-41B4-A2F7-F7F12839EC3EQ35992464-E617FD01-6B8E-4343-BEEB-1FAC84E3D30BQ36431837-FC942A37-37E2-4AE1-8A16-D47CDDB1021FQ37520823-51D1FCE4-FC98-4679-B96B-5F7C2337B468Q37698882-90E94636-19FC-4716-8725-E757355CE2E2Q38116560-305F474F-0464-4F3A-BC33-9D25EA75760FQ38120241-E6A00BAF-9BE6-470A-81AB-217C705C50D2Q38126374-F831E3AE-2002-40A3-9CB1-4711140D1D3FQ38181208-7E22C061-49B3-4DBA-8E36-50610414C036Q38182029-26ADB757-002F-4412-949C-5D54A6F9FFBBQ38191517-6EDC885C-5E66-41C3-80F3-57B449648DF4Q38590227-8C58E1E9-31C5-4F08-91B7-5C95AB0C2C89Q38766590-65BD0930-CABF-40F5-82C7-7B4FF14A8428Q38859432-8FED2F7D-4965-48C6-9C8B-DEBB270E222FQ39199991-F0830B56-A53F-4963-9702-4BB695A92876Q40173081-C334EA95-EB20-4429-A19D-EF07F62F099DQ41090275-774D3B3D-9D2C-4291-95D1-E687671A388FQ41714003-8589A8E0-EECB-41B8-B672-4FB0B8E26CA5Q47652227-997CF5FC-6AD7-4090-A051-D78D29041535Q47696462-03B38BD5-8A95-47FC-BA17-045A9EC497FEQ49195820-91ACF78E-3FDA-4F03-9FFC-C6D033A39A15Q49591511-EA62510A-2C13-41AD-B767-E112008D43BBQ50083275-AB262833-9F59-445C-B01B-93C884497DB0Q50998627-C5D83C64-7E51-425D-B820-3966967DBF3A
P2860
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mineralocorticoid receptor ant ...... idence into clinical practice.
@en
type
label
Mineralocorticoid receptor ant ...... idence into clinical practice.
@en
prefLabel
Mineralocorticoid receptor ant ...... idence into clinical practice.
@en
P2093
P50
P356
P1476
Mineralocorticoid receptor ant ...... idence into clinical practice.
@en
P2093
Adriaan A Voors
Domenic A Sica
George L Bakris
Gerasimos S Filippatos
Hani N Sabbah
Ileana L Piña
Johann Bauersachs
John J V McMurray
Robert J Mentz
Ziad A Massy
P304
P356
10.1093/EURHEARTJ/EHS257
P50
P577
2012-08-31T00:00:00Z